Mobile

Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

Mise à jour : Il y a 4 ans
Référence : NCT02707328

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.

Critère d'inclusion

  • pancreas cancer,Pancreatic cancer,Adenocarcinoma of the Pancreas,pancreas adenocarcinoma,PANCREATIC ADENOCARCINOMA'

Liens